Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Cut Your Canopy Growth Corp Bet by Half and Win Big

Canopy Growth has a first-mover advantage that puts it out front in the North American marijuana industry. Here’s the play I would make with CGC stock.   

7 Stocks to Buy Over $200

All of these stocks to buy are over $200-per-share. Although they might not be cheap, each is still worth owning. Here's why investors should consider each pick.

CBD Medicine Developments Provide a Really Solid Base for GWPH Stock

For those unfamiliar with Dravet syndrome, it’s a rare genetic condition that hits newborns and results in seizures caused by fever and involuntary muscle spasms. Young children who develop this condition tend to experience difficulty speaking, reduced motor skills, and hyperactivity.

7 Stocks to Buy That Aren’t in the Dow But Should Be

General Electric being removed from the Dow reminds us that businesses can come and go. Here are seven stocks to buy I’d like to see in the Dow. 

8 Reasons for Breaking Up Berkshire Hathaway, Inc., Evaluated

Buffett is the antithesis of Jamie Dimon. If he thought it would help shareholders wrap their arms around the entire business providing a sustainable buy-and-hold mentality, he already would have done it.